223 related articles for article (PubMed ID: 35880452)
21. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
22. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
[TBL] [Abstract][Full Text] [Related]
23. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
24. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
25. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
26. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
27. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
Schaefer IM; DeMatteo RP; Serrano C
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
29. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Naito Y; Nishida T; Doi T
Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
[TBL] [Abstract][Full Text] [Related]
31. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
32. Ripretinib (Qinlock) for GIST.
Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
[No Abstract] [Full Text] [Related]
33. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
36. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
[TBL] [Abstract][Full Text] [Related]
37. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
38. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith BD; Kaufman MD; Lu WP; Gupta A; Leary CB; Wise SC; Rutkoski TJ; Ahn YM; Al-Ani G; Bulfer SL; Caldwell TM; Chun L; Ensinger CL; Hood MM; McKinley A; Patt WC; Ruiz-Soto R; Su Y; Telikepalli H; Town A; Turner BA; Vogeti L; Vogeti S; Yates K; Janku F; Abdul Razak AR; Rosen O; Heinrich MC; Flynn DL
Cancer Cell; 2019 May; 35(5):738-751.e9. PubMed ID: 31085175
[TBL] [Abstract][Full Text] [Related]
39. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
40. Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.
Masucci MT; Motti ML; Minopoli M; Di Carluccio G; Carriero MV
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37046997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]